These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38805968)

  • 1. Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.
    Horska K; Kucera J; Drazanova E; Kuzminova G; Amchova P; Hrickova M; Ruda-Kucerova J; Skrede S
    Biomed Pharmacother; 2024 Jul; 176():116763. PubMed ID: 38805968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.
    Wu LM; Wang YX; Zhan Y; Liu AH; Wang YX; Shen HF; Wang YF; Wang LY; Tao ZB; Wang YQ
    Peptides; 2021 Nov; 145():170624. PubMed ID: 34375684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
    Horska K; Kotolova H; Karpisek M; Babinska Z; Hammer T; Prochazka J; Stark T; Micale V; Ruda-Kucerova J
    Toxicol Appl Pharmacol; 2020 Nov; 406():115214. PubMed ID: 32866524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
    Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
    Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
    Sharma AN; Ligade SS; Sharma JN; Shukla P; Elased KM; Lucot JB
    Metab Brain Dis; 2015 Apr; 30(2):519-27. PubMed ID: 25023888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
    Kimura T; Obata A; Shimoda M; Hirukawa H; Kanda-Kimura Y; Nogami Y; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Metab; 2018 Jun; 44(3):250-260. PubMed ID: 29525225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
    Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
    Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
    Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
    Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.